Skip to main content
Fig. 1 | Arthritis Research & Therapy

Fig. 1

From: Tumor necrosis factor alpha neutralization attenuates immune checkpoint inhibitor-induced activation of intermediate monocytes in synovial fluid mononuclear cells from patients with inflammatory arthritis

Fig. 1

MCP-1 production following treatment with pembrolizumab. A–C MCP-1 production in SFMCs (n = 16, 3 SpA patients, 5 PsA patients, and 8 RA patients) and PBMCs (n = 6, 3 SpA patients and 3 RA patients) from patients and healthy controls (n = 6) cultured for 48 h untreated (UT) or treated with pembrolizumab (Pembro) or LPS. D–F Data were normalized to untreated cultures and expressed as ratios. Data is presented as median with interquartile range. Log-transformed ratios were analyzed with the paired Student’s t-test. *P-value < 0.05, **P-value < 0.01, ***P-value < 0.001

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us